Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Free Cash Flow (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Free Cash Flow for 4 consecutive years, with -$14.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 7.93% to -$14.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$60.8 million, a 26.19% decrease, with the full-year FY2024 number at -$50.8 million, down 10.05% from a year prior.
  • Free Cash Flow was -$14.9 million for Q3 2025 at Orchestra BioMed Holdings, up from -$15.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$5.4 million in Q1 2022 to a low of -$16.7 million in Q1 2025.
  • A 4-year average of -$11.6 million and a median of -$11.0 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 168.4% in 2023, then grew 8.29% in 2024.
  • Orchestra BioMed Holdings' Free Cash Flow stood at -$8.8 million in 2022, then decreased by 24.7% to -$11.0 million in 2023, then decreased by 24.36% to -$13.6 million in 2024, then fell by 8.91% to -$14.9 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Free Cash Flow are -$14.9 million (Q3 2025), -$15.6 million (Q2 2025), and -$16.7 million (Q1 2025).